The Obama administration announced this month $80 million in new funding for Alzheimer’s disease research, adding to the $450 million the NIH currently spends. The NIH will receive $50 million in reallocated money for fiscal 2012, half of which will go to sequencing centers funded by the National Human Genome Research Institute to sequence the […]
The number of hectares of biotech crops increased 8% in 2011 to 160 million. Twenty-nine countries grew biotech crops last year, led by the US (43% of total hectares), Brazil (19%) and Argentina (15%). Twelve countries planted stacked-trait crops, which accounted for 42.2 million hectares. Brazil was the country whose hectarage of biotech crops grew […]
The percentage of NIH research grant applications that were funded fell 3% to a record low of 18% in fiscal 2011. The decline is mainly due to the funding of continuing multiyear R01 grants. Funding such grants cost the NIH an additional $189 million and accounted for 78% of available grant money. Another factor was […]
To increase sluggish returns on investment, pharmaceutical and biotechnology firms are relying more on CROs, according to a new report from the Economist Intelligence Unit (EIU). In the last two years, pharmaceutical and biotech firms have established 22 major partnerships with CROs, which now account for 40% of discovery and development (D&D). In September 2011, […]
According to the Industrial Research Institute’s (IRI) 28th annual “R&D Trends Forecast,” 53% of respondents plan to spend the same amount on R&D in 2012 as last year. The IRI surveyed R&D managers at 104 firms in multiple industries in July and August 2011. R&D budget increases of 2.5% to 5% are expected by 22% […]
To say that 2011 was a good year would be an understatement. Somewhat unexpectedly, 2011 results were much better than we could have hoped, given the strong rebound in 2010. So now is the time to look ahead to the coming year and the prospects for the analytical and life science instrument industry. Based on […]
Pharmaceutical and Biotechnology EvaluatePharma forecast that R&D spending by pharmaceutical companies will rise 1.0% this year to $134 billion, according to a June 2011 report. From now until 2016, R&D spending by drug companies is expected to grow an average of 2.5% annually to total $147 billion. EvaluatePharma forecasted prescription drug revenues to have a […]
This month, the EPA finalized US standards for mercury and air toxics emissions from power plants. The regulations are expected to affect 1,100 coal-fired units and 300 oil-fired units at a total of 600 power plants. Power plants are responsible for approximately 50% of mercury emissions and 77% of acid gas emissions. The standards provide […]
According to Battelle and R&D Magazine, R&D spending worldwide is estimated to increase 5.2% to $1,402.6 billion in 2012 measured in purchase powered parity, compared to growth of 6.5% in 2011. Asian R&D spending is expected to increase the fastest, rising 9% next year to $514.4 billion to account for 37% of total global R&D […]
In order to meet increasing demands for safety and cost effectiveness, more drugs are being developed with diagnostic tests to target specific patient populations. This summer, the FDA issued guidelines for drug and diagnostic combinations, and the FDA approved two such products: Xalkori for lung cancer and Zelboraf for treating melanoma. The Personalized Medicine Coalition […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
